Roivant Sciences subsidiary Pulmovant is on track for a Phase 2 test of mosliciguat as a treatment for pulmonary hypertension associated with interstitial lung disease. The inhaled drug offers a different mechanism of action and less burdensome dosing compared to United Therapeutics’ blockbuster PH-ILD drug, Tyvaso.
The post Bayer Asset Gives Roivant Sciences’ New ‘Vant’ a Shot at Besting a United Therapeutics Lung Drug appeared first on MedCity News.
